176 related articles for article (PubMed ID: 37669005)
1. Random Forest for Predicting Treatment Response to Radioiodine and Thyrotropin Suppression Therapy in Patients With Differentiated Thyroid Cancer But Without Structural Disease.
Sa R; Yang T; Zhang Z; Guan F
Oncologist; 2024 Jan; 29(1):e68-e80. PubMed ID: 37669005
[TBL] [Abstract][Full Text] [Related]
2. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine.
Kohlfuerst S; Igerc I; Lind P
Thyroid; 2005 Apr; 15(4):371-6. PubMed ID: 15876162
[TBL] [Abstract][Full Text] [Related]
4. Comparing the efficacy of thyroglobulin and thyroglobulin/ thyroid-stimulating hormone ratio models in predicting a successful response to radioactive iodine therapy.
Ju Y; Wang L; Cheng F; Huang F; Chen X; Song Q; Xiao J; Zhu X; Jia H
BMC Endocr Disord; 2023 Jan; 23(1):19. PubMed ID: 36670396
[TBL] [Abstract][Full Text] [Related]
5. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
6. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients.
Tatar FA; Morita E; Ituarte PH; Cavalieri RR; Duh QY; Price DC; Siperstein AE; Clark OH
World J Surg; 2001 Jun; 25(6):718-22. PubMed ID: 11376405
[TBL] [Abstract][Full Text] [Related]
7. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
Ma C; Xie J; Kuang A
J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients.
Gambale C; Prete A; Contartese L; Torregrossa L; Bianchi F; Molinaro E; Materazzi G; Elisei R; Matrone A
Eur Thyroid J; 2023 Dec; 12(6):. PubMed ID: 37855417
[TBL] [Abstract][Full Text] [Related]
9. Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.
Zhao T; Liang J; Guo Z; Li J; Lin Y
Endocrine; 2016 Jul; 53(1):166-73. PubMed ID: 26782372
[TBL] [Abstract][Full Text] [Related]
10. A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer.
Meng C; Song J; Long W; Mu Z; Sun Y; Liang J; Lin Y
Front Endocrinol (Lausanne); 2023; 14():1109439. PubMed ID: 36843580
[TBL] [Abstract][Full Text] [Related]
11. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
Koh JM; Kim ES; Ryu JS; Hong SJ; Kim WB; Shong YK
Clin Endocrinol (Oxf); 2003 Apr; 58(4):421-7. PubMed ID: 12641624
[TBL] [Abstract][Full Text] [Related]
12. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
Chao M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
[TBL] [Abstract][Full Text] [Related]
13. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
14. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
[TBL] [Abstract][Full Text] [Related]
15. Analysis of correlation factors influencing the outcome of initial 131I remnant ablative therapy in intermediate- to high-risk patients with papillary thyroid microcarcinoma.
Wu R; Liu W; Li N; Wang X; Sun D; Ji Y; Jia Q; Tan J; Zheng W
Nucl Med Commun; 2022 Jun; 43(6):669-674. PubMed ID: 35351838
[TBL] [Abstract][Full Text] [Related]
16. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions.
Mazzaferri EL; Kloos RT
Thyroid; 2000 Sep; 10(9):767-78. PubMed ID: 11041454
[TBL] [Abstract][Full Text] [Related]
17. TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer.
Ju N; Hou L; Song H; Qiu Z; Wang Y; Sun Z; Luo Q; Shen C
Eur Thyroid J; 2023 Aug; 12(4):. PubMed ID: 37022724
[TBL] [Abstract][Full Text] [Related]
18. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.
Berg G; Lindstedt G; Suurküla M; Jansson S
J Endocrinol Invest; 2002 Jan; 25(1):44-52. PubMed ID: 11883865
[TBL] [Abstract][Full Text] [Related]
19. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients.
Campennì A; Ruggeri RM; Siracusa M; Comis AD; Romano D; Vento A; Lanzafame H; Capoccetti F; Alibrandi A; Baldari S; Giovanella L
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2466-2475. PubMed ID: 33416957
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]